Drug Pricing

Pharmalot By Ed Silverman

Medicines Patent Pool expands deal for access to key HIV drug to several upper middle-income countries

Politics By Nicholas Florko

Which pricey drugs will Trump’s international pricing policy target?

First Opinion By Robin Feldman

Make list price the touchstone for drug pricing across the supply chain

Pharmalot By Ed Silverman

NIH fails to disclose enough details about drug licensing, watchdog report finds

Politics By Kate Sheridan

‘I don’t think it goes away’: Pharma experts weigh in on the next 4 years of drug pricing reform

Pharmalot By Ed Silverman

Americans are spending more on specialty medicines, despite rebates given to payers

Politics By Lev Facher, Nicholas Florko, Andrew Joseph, and Kate Sheridan

Doctors in Congress, new e-cigarette taxes, stem cells, and abortion rights: Here’s what STAT is watching tonight

Pharmalot By Ed Silverman

Gilead faces pressure to relinquish valuable FDA voucher awarded with remdesivir approval

Pharmalot By Ed Silverman

Takeda price hikes for a GI drug may give some patients another kind of stomachache

Pharmalot By Ed Silverman

Novartis move to defuse controversy over U.S. drug discount program is rebuffed

Politics By Nicholas Florko and Kate Sheridan

Biden’s policies could spell trouble for biotech — but industry CEOs are backing him anyway

Politics By Lev Facher

Trump administration finalizes rule forcing insurers to disclose negotiated prices, including for drugs

Pharmalot By Ed Silverman

‘Dying waiting’: Advocates urge Vertex to widen global access to cystic fibrosis drugs

Don't Miss By STAT staff

As STAT turns 5, a look back at science and medicine’s biggest headlines and controversies

Pharmalot By Ed Silverman

Health Canada releases final version of controversial regulations for controlling drug prices

Politics By Lev Facher

As election nears, Trump leans on health care agencies to aid his campaign

D.C. Diagnosis By Nicholas Florko

Will this be the most-watched FDA meeting ever?

Pharmalot By Ed Silverman

AstraZeneca loses first-of-its-kind lawsuit filed by Dutch insurer over patent maneuver

Pharmalot By Ed Silverman

Insulin in the U.S. cost up to 10 times more than in nearly three dozen other OECD countries

Pharmalot By Ed Silverman

What doubts? New forecast says biosimilars will cut U.S. drug spending by $100 billion in five years

Politics By Nicholas Florko

‘Are you an American, sir?’: Lawmakers interrogate Amgen, Novartis, Mallinckrodt executives on why U.S. prices are so high

Pharmalot By Ed Silverman

Pharmalittle: FDA extends probe into AstraZeneca Covid-19 vaccine; House committee blasts pharma CEOs over prices

Politics By Nicholas Florko

‘You just got better at making money’: Democrats blast Celgene, Teva for price hikes detailed in internal documents

Pharmalot By Ed Silverman

For the first time, drug makers and PBMs must jointly face an insulin price fixing lawsuit

Politics By Nicholas Florko

Most Read

Trump’s ‘most favored nation’ executive order on drug prices is a scam for seniors

I have spinal muscular atrophy. Critics of the $2 million new gene therapy are missing the point

Trump claims his policies made insulin ‘so cheap, it’s like water.’ But for most people, it costs just as much as before

9 ways Covid-19 may forever upend the U.S. health care industry

Pharmalittle: AstraZeneca Covid-19 vaccine shows promise in elderly; surprise rule will require insurers to estimate out-of-pocket drug costs

Remdesivir’s hefty price tag ignores NIH investment in its creation

Trump’s making last-minute drug pricing reforms — and surprisingly, Democrats want Biden to keep the biggest one

When off-label may mean off-target: How would doctors and insurers navigate demand for a new, narrow Alzheimer’s drug?

All Coverage

Medicines Patent Pool expands deal for access to key HIV drug to several upper middle-income countries

Which pricey drugs will Trump’s international pricing policy target?

Make list price the touchstone for drug pricing across the supply chain

NIH fails to disclose enough details about drug licensing, watchdog report finds

‘I don’t think it goes away’: Pharma experts weigh in on the next 4 years of drug pricing reform

Americans are spending more on specialty medicines, despite rebates given to payers

Doctors in Congress, new e-cigarette taxes, stem cells, and abortion rights: Here’s what STAT is watching tonight

Gilead faces pressure to relinquish valuable FDA voucher awarded with remdesivir approval

Takeda price hikes for a GI drug may give some patients another kind of stomachache

Novartis move to defuse controversy over U.S. drug discount program is rebuffed

Biden’s policies could spell trouble for biotech — but industry CEOs are backing him anyway

Trump administration finalizes rule forcing insurers to disclose negotiated prices, including for drugs

‘Dying waiting’: Advocates urge Vertex to widen global access to cystic fibrosis drugs

As STAT turns 5, a look back at science and medicine’s biggest headlines and controversies

Health Canada releases final version of controversial regulations for controlling drug prices

As election nears, Trump leans on health care agencies to aid his campaign

Will this be the most-watched FDA meeting ever?

AstraZeneca loses first-of-its-kind lawsuit filed by Dutch insurer over patent maneuver

Insulin in the U.S. cost up to 10 times more than in nearly three dozen other OECD countries

What doubts? New forecast says biosimilars will cut U.S. drug spending by $100 billion in five years

‘Are you an American, sir?’: Lawmakers interrogate Amgen, Novartis, Mallinckrodt executives on why U.S. prices are so high

Pharmalittle: FDA extends probe into AstraZeneca Covid-19 vaccine; House committee blasts pharma CEOs over prices

‘You just got better at making money’: Democrats blast Celgene, Teva for price hikes detailed in internal documents

For the first time, drug makers and PBMs must jointly face an insulin price fixing lawsuit

Congressional investigation reveals Celgene, Teva plotted to keep drug prices high